ProofPilot, a New York-based leading Software as a Service (SaaS) clinical trial research platform, announced the closing of more than $12 million in Series B financing.
The round was led by Mitsui & Co. (U.S.A.), Inc., with Sopris Capital, LLC, First Trust Capital Partners, LLC, and Excelra, among others, participating in this round.
The fully-integrated Software as a Service (SaaS) research platform aims to transform the current clinical trial model.
Company: ProofPilot Inc.
Round: Series B
Funding Month: April 2022
Lead Investors: Mitsui & Co. (U.S.A.), Inc.
Additional Investors: Sopris Capital, LLC, First Trust Capital Partners, LLC, and Excelra
Company Website: https://www.proofpilot.com/
Software Category: Software as a Service (SaaS) Research Platform
About the Company: Founded in 2014 by Matthew Amsden, ProofPilot is Software as a Service (SaaS) research platform to design, launch, and participate in research studies. ProofPilot enables Digital Design and Virtual Orchestration of activities to empower anyone to execute a wide variety of clinical studies with speed, ease, and economy. ProofPilot is revolutionizing the complex and arduous clinical trial market by offering a fully digitized platform with self-design study, trial process management, and remote source verification capabilities. ProofPilot was designed as a solution for Life Science companies with ProofPilot Rx, as well as wellness interventions with its product ProofPilot 365. Headquarters in New York City, New York.